When Does a Wound Qualify for Skin Substitute Application?

Skin Substitute Eligibility FAQ

Not every wound qualifies for a skin substitute application. Medicare coverage for skin substitutes is conditional — the wound must meet specific clinical criteria, the provider must demonstrate that conservative treatment has failed, and the documentation must prove both. Missing any of these elements results in a denied claim or, worse, a post-payment recoupment on audit.

Which wound types are eligible for skin substitute application?

Skin substitutes are covered for chronic wounds that have not responded to standard wound care. The two primary qualifying wound types are:

Chronic diabetic foot ulcers (DFUs). The ulcer must be chronic — typically defined as present for at least 30 days despite appropriate standard wound care. Acute surgical wounds, traumatic lacerations, and new ulcerations do not qualify. The wound must be a full-thickness ulcer (Wagner Grade 1 or greater) that has not adequately responded to conservative management.

Chronic venous leg ulcers (VLUs). The ulcer must result from venous insufficiency and must have persisted despite conservative therapy including sustained compression. An acute venous wound from trauma or surgery does not meet the threshold. The wound must demonstrate chronicity through documented duration and treatment history.

Some LCDs also cover arterial ulcers and other chronic wound types in specific circumstances, but DFUs and VLUs represent the overwhelming majority of covered applications. The governing principle across all wound types is the same: the wound must be chronic, not acute, and must have failed conservative treatment before skin substitute application is considered medically necessary.

What is the failed conservative therapy requirement?

Medicare requires documentation of at least four weeks of appropriate standard wound care before a skin substitute is considered eligible. This is not a waiting period — it is an evidence requirement. The record must show that the wound received adequate conventional treatment and did not respond sufficiently.

Conservative therapy must include, where clinically appropriate:

Debridement of necrotic tissue to maintain a clean wound bed
Offloading for plantar DFUs (appropriate footwear, total contact casting, or removable cast walkers)
Compression therapy for VLUs (multi-layer compression bandaging or compression stockings with adequate pressure)
Infection management including cultures and appropriate antimicrobial therapy when indicated
Moisture management with appropriate wound dressings
Nutritional optimization and glycemic control for diabetic patients

The four-week minimum is a floor, not a ceiling. Some LCDs require longer durations or more specific treatment protocols. The documentation must address each component of conservative care and explain why the wound did not respond adequately.

What wound bed preparation is required before application?

Even after conservative therapy has failed, the wound bed itself must meet certain conditions before a skin substitute can be applied. Applying a graft to an unprepared wound bed wastes the product and generates a claim that cannot be defended on audit.

The wound bed must be:

Clean and free of necrotic tissue. Sharp debridement should have been performed to remove devitalized tissue prior to application. A wound bed with significant slough or eschar is not ready for a skin substitute.
Granulating. The wound should show viable granulation tissue, indicating the wound bed can support graft incorporation.
Free of clinical infection. Active wound infection must be treated and resolved before application. Applying a skin substitute to an infected wound bed is clinically contraindicated and will not meet coverage criteria.
Adequately vascularized. The wound must have sufficient blood supply to support healing. For lower extremity wounds, vascular assessment (ABI or other perfusion testing) should be documented.

How do LCD criteria vary by MAC jurisdiction?

Skin substitute coverage is governed by Local Coverage Determinations, and these vary by Medicare Administrative Contractor. The core clinical principles are consistent — chronicity, failed conservative therapy, wound bed preparation — but the specific requirements differ in important ways.

Key LCDs governing skin substitutes include L33831, L37166, and L38720, among others depending on jurisdiction. Differences between MACs may include:

Duration of required conservative therapy (30 days vs. longer)
Specific documentation elements required in each visit note
Frequency limits on applications before the KX modifier is required
Which wound types beyond DFU and VLU are covered
Maximum wound size or total square centimeters covered per application

Practices operating across multiple MAC jurisdictions must track which LCD governs each patient based on the patient's geographic location, not the practice's billing address. A single practice billing in two MAC regions may need to meet two different documentation standards for identical clinical scenarios.

For a detailed walkthrough of LCD compliance requirements, see our LCD compliance guide.

What documentation proves eligibility?

The documentation burden for skin substitute eligibility is heavier than for most wound care services. Every element of the eligibility determination must be traceable in the medical record.

Serial wound measurements showing insufficient progress. The standard benchmark is less than 50% wound area reduction after four weeks of conservative therapy. Measurements at baseline and at regular intervals (weekly or biweekly) must be documented with consistent technique — length, width, and depth using the same measurement method across visits.

Treatment log covering the conservative therapy period. Each visit during the conservative therapy period must document what was done, how the wound responded, and what the plan is going forward. A single note stating "patient received wound care for 4 weeks" does not satisfy the requirement.

Wound bed description at the time of application. The note must describe the tissue composition (percentage granulation, slough, eschar), wound edges, periwound condition, and absence of clinical infection.

Medical necessity rationale. The provider must articulate why a skin substitute is the appropriate next step given the wound's failure to respond to conservative measures, and why continued conservative care alone is unlikely to achieve closure.

For billing and coding specifics once eligibility is established, see the skin substitute billing guide. For prior authorization requirements that may apply depending on the payer, see our prior authorization overview.